Use of raspberry ketone in immune combination therapy for pancreatic cancer

By combining raspberry ketone with chloroquine or PD-1 inhibitors, the problem of immune escape caused by the tumor microenvironment in pancreatic cancer treatment was solved, significantly prolonging the survival of tumor-bearing mice and inhibiting tumor growth, providing a new immunotherapy regimen for pancreatic cancer.

CN122140672APending Publication Date: 2026-06-05HARBIN INST OF TECH +1

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
HARBIN INST OF TECH
Filing Date
2026-04-30
Publication Date
2026-06-05

Smart Images

  • Figure CN122140672A_ABST
    Figure CN122140672A_ABST
Patent Text Reader

Abstract

The application of raspberry ketone in the immunotherapy of pancreatic cancer belongs to the technical field of biological medicine, and provides the application of raspberry ketone in the immunotherapy of pancreatic cancer. The application discloses that raspberry ketone can specifically and widely up-regulate the expression of MHC-I molecules on the surface of pancreatic cancer cells, and significantly enhances the infiltration and function of anti-tumor effector T cells in the tumor immune microenvironment. In-vivo and in-vitro experiments prove that raspberry ketone can reverse tumor immune escape by up-regulating MHC-I, and after being combined with a PD-1 immune checkpoint inhibitor, the raspberry ketone can produce a significant synergistic anti-tumor effect, significantly inhibit the growth of pancreatic cancer and prolong the survival period of tumor-bearing mice. The application provides a new strategy of combining a natural small molecule immunomodulator with an existing immunotherapy, and provides an innovative solution and a drug candidate for overcoming the difficulty of pancreatic cancer tolerance to immunotherapy.
Need to check novelty before this filing date? Find Prior Art